OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley
This article was originally published in The Tan Sheet
Executive Summary
Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say
You may also be interested in...
Novartis CEO Jimenez Highlights OTC Switches, Consumer Acquisitions
Incoming Novartis CEO Joe Jimenez plans to expand the Swiss firm's consumer health division over the next few years after he takes the reins from his predecessor Daniel Vasella
Novartis CEO Jimenez Highlights OTC Switches, Consumer Acquisitions
Incoming Novartis CEO Joe Jimenez plans to expand the Swiss firm's consumer health division over the next few years after he takes the reins from his predecessor Daniel Vasella
Novartis CEO Jimenez Highlights OTC Switches, Consumer Acquisitions
Incoming Novartis CEO Joe Jimenez plans to expand the Swiss firm's consumer health division over the next few years after he takes the reins from his predecessor Daniel Vasella